Coya Therapeutics, Inc. (COYA)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$50.7M
Cash & Equivalents
$6.2M
Quarterly Burn Rate
25 mo
Est. Cash Runway
$123M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2027-01-01 Phase2 Readout —

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT07161999 Study of COYA 302 for the Treatment of ALS PHASE2 Recruiting 120

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for COYA.

SEC EDGAR Filings

All SEC filings for Coya Therapeutics, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.